Brian Anderson

HealthEdge Investment Partners invests in both public and private lower middle market companies located in the United States with an EBITDA of USD 2 - 15 million and revenues of USD 5 - 75 million. The firm target companies operating in the field of the healthcare sector. It provides financing for buyouts, recapitalizations and growth capital requirements. It also makes majority and significant minority control investments in companies.

Tampa Bay Research Institute (TBRI) is an independent biomedical research institute based in St. Petersburg, FL. TBRI focuses on biomedical research using a neutral, science-based approach. Since its formation in 1981, TBRI has prioritized allocating resources to promising areas of scientific study rather than non-scientific requirements imposed by outside or industry funding sources. TBRI collaborates with universities and hospitals worldwide, serving as a scientific resource. The institute has conducted scientific collaborations with prestigious institutions such as All Children's Hospital, Eckerd College, Emory University, the Howard Hughes Medical Institute at UCLA, Johns Hopkins University, the Kitasato Institute, the Moffitt Cancer Center at the University of South Florida (USF), St. Pete College (SPC), Suncoast Hospital, Tampa General Hospital, the University of Chicago, and the University of Montreal. TBRI has also provided training to numerous undergraduate and graduate students, as well as postdoctoral fellows. United Capital Funding Corp. is a corporate supporter and partner of TBRI.

Manufactures medical devices

Provides hospital medicine and post-acute services

Designs, manufactures and distributes custom in-ear communication & hearing protection products

Provides tech-enabled coding and clinical documentation review, revenue cycle, compliance, technology & education services to healthcare industry

Robert W Baird invests in lower middle market companies located in the United States, United Kingdom and Asia with an EBITDA of USD 5 – 15 million and revenues of USD 40 – 260 million. The firm focuses on B2B tech & services, healthcare, industrial solutions & technology and services sectors. It participates in later, growth and buyout stage capital transactions with an investment size of USD 25 – 75 million. The firm acquires majority, minority and controlling interest, and makes co-investments. It also takes a seat on the board of directors.

Provides a transaction platform that enables billing for both pharmacy and medical benefits

Distributes incontinence and catheter-related products